Dimethyl Sulfoxide
Apexbio Technology LLC Protionamide 14222-60-7 10mM (in 1mL DMSO)
Protionamide is a thiophene-derived antibacterial compound that inhibits the synthesis of mycolic acids a major component of the mycobacterial cell wall Through disruption of mycolic acid biosynthesis it interferes with cell wall integrity exhibiting antibacterial activity against pathogenic mycobacteria Protionamide is commonly employed in research involving Mycobacterium tuberculosis and Mycobacterium leprae primarily for investigating molecular mechanisms underlying drug resistance and cell wall biosynthesis pathways In laboratory experiments this compound is frequently utilized in vitro for cultivation assays antimicrobial screening and studies on synergistic effects when combined with other antimycobacterial agents It demonstrates reported IC50 values in the micromolar range dependent on experimental conditions and mycobacterial strains used
Apexbio Technology LLC Pralatrexate 146464-95-1 10mM (in 1mL DMSO)
Pralatrexate (CAS 146464-95-1) is a small molecule inhibitor targeting dihydrofolate reductase (DHFR) with a Ki value of 45 nM DHFR mediates the reduction of dihydrofolate to tetrahydrofolate a critical cofactor in purine thymidylate and amino acid biosynthesis Pralatrexate exhibits high affinity for folylpolyglutamate synthetase (FPGS) and reduced folate carrier-1 (RFC-1) facilitating intracellular accumulation It demonstrates notable antiproliferative activity against various human cancer cell lines in vitro and reduces tumor growth in NSCLC xenograft models indicating its suitability for oncology research
Apexbio Technology LLC DBeQ 177355-84-9 10mM (in 1mL DMSO)
DBeQ (CAS 177355-84-9) is a selective and reversible inhibitor of the ATPase p97 (also known as VCP or Cdc48 in yeast) exhibiting an IC50 value of approximately 1 5 M p97 is an essential abundantly expressed hexameric AAA ATPase implicated in multiple cellular processes including endoplasmic reticulum-associated degradation (ERAD) mitochondrial-associated degradation autophagy maturation and regulation of transcription factors DBeQ inhibits p97 by specifically targeting its D1 and D2 ATPase domains leading to blockage of ERAD and autophagosome maturation Research applications of DBeQ include investigating protein homeostasis cancer biology and apoptosis induction mediated through caspases-3 and -9 activation
Apexbio Technology LLC PD184352 (CI-1040) 212631-79-3 10mM (in 1mL DMSO)
PD184352 (CI-1040 CAS 212631-79-3) is a benzhydroxamate derivative that selectively inhibits the MEK1/2 kinases members of the MAP kinase kinase (MAPKK) family It interacts with a hydrophobic pocket adjacent to the Mg-ATP binding region of MEK1/2 triggering conformational shifts that favor the inactive non-phosphorylated state of these enzymes Acting via an ATP- and ERK1/2-independent inhibitory mechanism PD184352 robustly suppresses purified MEK1 enzyme activity (IC50 17 nM) Preclinical research demonstrates efficacy in reducing tumor growth notably in murine xenograft models of colon carcinoma underscoring its utility as a research tool in oncology
Apexbio Technology LLC CPI-169 1450655-76-1 10mM (in 1mL DMSO)
CPI-169 is a selective small-molecule inhibitor targeting enhancer of zeste homolog 2 (EZH2) a catalytic component of polycomb repressive complex 2 (PRC2) By inhibiting EZH2 enzymatic activity CPI-169 suppresses methylation at histone H3 lysine 27 (H3K27me3) thereby altering chromatin structure and gene expression profiles Pharmacological experiments demonstrate inhibition of EZH2 with subnanomolar IC50 values and cellular studies indicate reductions of H3K27 trimethylation at nanomolar concentrations CPI-169 has been utilized experimentally to investigate EZH2-dependent epigenetic processes cell proliferation apoptosis pathways and therapeutic potential particularly in lymphoma and cancer biology studies employing in vitro and in vivo models
Apexbio Technology LLC Idarubicin HCl 57852-57-0 10mM (in 1mL DMSO)
Idarubicin hydrochloride an anthracycline derivative structurally related to daunorubicin acts primarily by inhibiting DNA topoisomerase II It exerts cytotoxic effects through stabilization of DNA-topoisomerase II intercalation complexes inducing DNA strand breaks and apoptosis Idarubicin can be enzymatically activated intracellularly via NADPH-cytochrome C reductase enhancing DNA damage Experimentally it is commonly utilized in leukemia research particularly acute myeloid leukemia (AML) assessing cellular response to DNA damage apoptosis induction and mechanisms underlying drug resistance Idarubicin exhibits IC50 values typically ranging from low nanomolar to micromolar concentrations depending on cell line and assay conditions
Apexbio Technology LLC CP-673451 343787-29-1 10mM (in 1mL DMSO)
CP-673451 (CAS 343787-29-1) is an ATP-competitive inhibitor with specificity for platelet-derived growth factor receptors (PDGFR- / ) It exhibits inhibitory potency with IC50 values of 10 nM for PDGFR- and 1 nM for PDGFR- while demonstrating significantly less inhibition toward kinases such as VEGFR-1 VEGFR-2 Lck TIE-2 and EGFR In cellular assays CP-673451 effectively inhibits PDGFR- phosphorylation in PAE- cells (IC50 6 4 nM) and reduces c-kit activity in H526 cells at micromolar range Its anticancer efficacy has been established by suppressing tumor growth and vascularization in xenograft models indicating its potential utility in cancer research and angiogenesis studies
Apexbio Technology LLC Etonogestrel(Synonyms: 3-Ketodesogestrel, Implanon, Nexplanon, ORG-3236, 11-Methylenelevonorgestrel), 10mM (in 1mL DMSO), CAS: 54048-10-1.
Etonogestrel (CAS 54048-10-1) is a synthetic steroidal molecule derived as the biologically active metabolite of the progestin desogestrel Structurally it belongs to the 19-nortestosterone class and acts primarily through potent binding and agonist activity at progesterone receptors Through this receptor binding it modulates various physiological processes including ovulation suppression cervical mucus viscosity enhancement and endometrial alteration Etonogestrel serves as a widely researched hormonal contraceptive with applications in reproductive biology studies endocrinological research and pharmaceutical development
Apexbio Technology LLC MK-8245 1030612-90-8 10mM (in 1mL DMSO)
MK-8245 (CAS 1030612-90-8) is a potent liver-selective small molecule inhibitor of stearoyl-CoA desaturase (SCD) SCD1 catalyzes fatty acid desaturation and represents a target for treating type II diabetes obesity dyslipidemia and other metabolic disorders MK-8245 demonstrates strong inhibitory activity against rat mouse and human SCD1 with an IC50 of approximately 1 nM and displays liver-specific tissue distribution mediated by organic anion transporting polypeptides (OATPs) Animal studies revealed MK-8245 reduces blood glucose levels and hepatic triglycerides dose-dependently supporting its application in metabolic disease research
Apexbio Technology LLC CUDC-907 1339928-25-4 10mM (in 1mL DMSO)
CUDC-907 (CAS 1339928-25-4) is a dual inhibitor targeting histone deacetylases (HDACs 1 2 3 10) and class I phosphatidylinositol 3-kinases (PI3K) It exhibits nanomolar inhibitory activity against these enzymes blocking PI3K-mediated Akt signaling and increasing acetylation of histones and non-histone substrates (e g tubulin p53) In cancer cell models CUDC-907 induces G2-M phase arrest and reduces phosphorylation of downstream proteins such as p70S6 4EBP-1 MEK STAT3 and SRC Preclinical studies demonstrate its anti-tumor activity in lymphoma and NSCLC xenografts making it relevant for oncology research
Apexbio Technology LLC PF-477736 952021-60-2 10mM (in 1mL DMSO)
PF-477736 is an ATP-competitive small-molecule inhibitor of checkpoint kinase 1 (Chk1) It selectively inhibits Chk1 kinase activity demonstrating nanomolar inhibitory potency in kinase assays and exhibits lower affinity toward related kinases such as CDK1 and Chk2 In vitro studies utilizing human cancer cell lines show PF-477736 disrupts Chk1-dependent G2-phase cell-cycle arrest induced by DNA-damaging agents preferentially targeting tumor cells with compromised p53 function while minimizing cytotoxicity to normal cells PF-477736 is widely utilized experimentally to study DNA damage response mechanisms potential chemosensitizing effects and therapeutic implications for cancers harboring p53 mutations
Apexbio Technology LLC BV6 1001600-56-1 10mM (in 1mL DMSO)
BV6 (CAS 1001600-56-1) is a selective inhibitor targeting the inhibitor of apoptosis protein (IAP) family The IAP family includes proteins such as XIAP c-IAP1 and c-IAP2 that regulate programmed cell death pathways BV6 induces apoptosis and sensitizes cancer cells to chemotherapeutic agents and radiation by decreasing expression levels of IAPs including XIAP and c-IAP1 In vitro treatment with BV6 exhibited an IC50 of 7 2 M in H460 non-small cell lung carcinoma cells and enhanced their response to radiation BV6 is employed in research exploring cancer cell apoptosis modulation and therapeutic resistance
Apexbio Technology LLC STF-62247 315702-99-9 10mM (in 1mL DMSO)
STF-62247 (CAS 315702-99-9) is a small molecule that selectively targets renal cell carcinoma (RCC) cells carrying von Hippel-Lindau (VHL) gene deletions It exhibits cytotoxicity in both wild-type and VHL-deficient RCC cells via a mechanism independent of hypoxia-inducible factor (HIF) with reported IC50 values of 16 M and 0 625 M respectively In VHL-deficient RCC cells STF-62247 induces acidification autophagy and subsequent apoptotic cell death In mouse xenograft models bearing VHL-deficient SN12C tumors STF-62247 significantly reduced tumor growth This compound is useful for studying therapeutic strategies targeting VHL-deficient tumors
Apexbio Technology LLC JNJ-26481585 875320-29-9 10mM (in 1mL DMSO)
JNJ-26481585 (CAS 875320-29-9) is a small-molecule inhibitor targeting class I histone deacetylases (HDACs) specifically HDAC1 HDAC2 and HDAC3 with reported IC50 values of 0 11 0 33 and 4 8 nM respectively It exhibits potent anti-proliferative activity across various human cancer cell lines including lung breast colon prostate ovarian and brain cancers (IC50 range 3 1 246 nM) Mechanistically JNJ-26481585 induces histone H3 acetylation alleviates HDAC-mediated repression of the p21waf1 cip1 promoter and promotes apoptosis in colorectal cancer cell models Consequently this compound serves as a research tool for cancer epigenetics and therapeutic assessment
